The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...
Among adults with evidence of systemic mast cell activation, bone marrow samples allowed for detection of 13 additional patients with the KIT D816V mutation that were not detected in peripheral blood, ...
The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.
"Brittany's story is a testament to resilience (and) the strength of family ... Her family's love and support were essential ...
Burlington Free Press on MSN
Canadian wildfire smoke made asthma worse for Vermont kids, says UVM
Asthma symptoms worsened in children in Vermont and upstate New York exposed to smoke from Canadian wildfires, according to a recent study by UVM.
The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
FDA approves 2-dose biologic Exdensur for severe eosinophilic asthma in patients 12 and older, reducing exacerbations and hospital visits.
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...
The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback